Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria
- PMID: 38008108
- DOI: 10.1016/S0140-6736(23)02188-8
Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria
Conflict of interest statement
EN has been a speaker or consultant, or has received investigator-initiated research funding from AbbVie, Arcutis, Bausch Health, Boehringer Ingelheim International, Bristol Myers Squibb, Galderma, Janssen, LEO Pharma, Medexus, Novartis Pharmaceuticals, Pfizer, Sanofi Genzyme, Sun Pharmaceuticals, Eli Lilly, and UCB. EN is the founder of Montreal Derm FilEZ website, which is a non-profit educational resource. SM declares no competing interests. The authors received no financial support for the authorship or publication of this comment.
Comment on
-
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
